Peter Campbell

Peter Campbell, CSO of Quotient Therapeutics, discusses his journey from a traditional medical background in New Zealand to becoming a pioneer in cancer genomics. He shares insights from his time at the Sanger Institute, highlighting groundbreaking cancer sequencing projects and the evolution of genomic research. Campbell emphasizes the importance of understanding genetic mutations for personalized medicine, collaborations with Pfizer for innovative therapies, and how adaptive mutations impact cell regeneration. His passion for translating genomic insights into real-world applications is truly inspiring.